Adenosine has previously been shown to limit the proliferation and maturation of lymphocytic immune cell subsets (126, 134), and increased immune infiltrate in to the tumor core has been observed in response to co-targeting CD73 and A2AR in preclinical models (133). Here, ADORA2A is linked to neoplasm.